AstraZeneca strikes clinical collaboration with Summit to test ADC sonesitatug vedotin with ivonescimab in GI cancers
Bitget2026/09/29 10:42- AstraZeneca agreed to invest USD 2 billion in Summit Therapeutics through newly issued preferred stock convertible to common shares.
- Investment implies rights equivalent to about 12% of Summit’s outstanding common stock, or about 10.6% on a fully diluted basis.
- Separate clinical collaboration will test sonesitatug vedotin, a Claudin-18.2 ADC, combined with Summit’s PD-1/VEGF bispecific ivonescimab in GI cancers.
- Companies will supply their own medicines for combination trials, share trial costs, retain development and commercial rights to their respective products.
- Memorandum of understanding targets a broader global program pairing ivonescimab with AstraZeneca oncology drugs, including additional ADCs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Domestic sales "underperform," PepsiCo (PEP.US) launches mass layoffs of thousands in North America
PepsiCo North America has cut about 1,000 jobs to streamline operations, as beverage sales in the third quarter fell by 2% year-on-year and the full-year profit outlook has been revised downward.
WLFI: Token buyback will be carried out on Aster through a public wallet
Crypto prices
More
